Novartis' Cosentyx Wins FDA Approval As First Anti-IL-17 Biologic For Polymyalgia Rheumatica

Novartis AG (NVS) announced FDA approval for Cosentyx 150 mg to treat polymyalgia rheumatica in adults unresponsive to corticosteroids. The approval, based on the REPLENISH trial, makes Cosentyx the first anti-IL-17 biologic for this condition. NVS shares closed at $160.20, down 0.19%.

Original reporting
Published Nov 17, 2026, 6:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 7:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Novartis' Cosentyx Wins FDA Approval As First Anti-IL-17 Biologic For Polymyalgia Rheumatica — source image
Decision brief

The 30-second read

$NVSBullishMed
01

Why it matters

A new FDA-labeled indication can change the addressable market and reimbursement pathway for Cosentyx, while safety signals may affect prescribing behavior and post-marketing surveillance expectations.

02

Market read

Traders may reassess Cosentyx’s growth trajectory and near-term sentiment for Novartis following a first-in-class anti-IL-17 biologic approval for PMR.

03

What to watch

The article notes a fatal cryptococcal meningitis case and higher hypersensitivity/UTI rates, which could influence clinician comfort, risk management, and formulary decisions.

Relevance 7/10Novelty 8/10Timing: pre-market today (published early morning)

Background

Cosentyx (secukinumab) is already approved for multiple inflammatory conditions; this FDA action adds polymyalgia rheumatica as an 11th US indication.

Company-level read

Ticker impact

$NVSBullishHigh confidence
Context

Novartis said the FDA approved Cosentyx 150 mg for polymyalgia rheumatica, making it the first anti-IL-17 biologic for the indication.

Expected impact

Likely positive bias as the market prices in new indication-driven sales growth, tempered by attention to reported serious adverse events.

Evidence & confidence

The article is a direct, primary FDA approval for a new indication with trial efficacy numbers and safety notes, which typically drives near-term sentiment for the issuer’s commercial outlook.

Market effects

Reinforces IL-17 pathway competitiveness in inflammatory rheumatology and may intensify payer and prescriber evaluation of biologic sequencing versus steroids.

US label expansion can accelerate US prescribing and reimbursement discussions; Japan and other filings are pending.

If Japan and other regulators follow, it could broaden the commercial footprint beyond the US and support longer-dated growth expectations.

Counterpoint

Approval does not guarantee rapid uptake; PMR patients may remain steroid-centric, and real-world adoption could lag trial outcomes and payer restrictions.

Key entities

  • Novartis AG

    Issuer of Cosentyx, which received FDA approval for polymyalgia rheumatica.

  • Cosentyx (secukinumab)

    Anti-IL-17A biologic approved for PMR 150 mg in adults with inadequate response to corticosteroids or intolerance to steroid tapering.

  • FDA

    Approved the new PMR indication based on the Phase 3 REPLENISH trial.

Related articles

$NVSMed

Novartis wins FDA approval for Cosentyx in polymyalgia rheumatica

Novartis announced FDA approval for Cosentyx (secukinumab) to treat polymyalgia rheumatica in adults unresponsive to corticosteroids. The 150-mg dose showed 40.5% remission at Week 52 vs. 20.5% for placebo. This is Cosentyx's 11th U.S. indication. The approval follows positive Phase III trial results, with the drug demonstrating steroid-sparing effects. Novartis also noted ongoing regulatory reviews in other regions.

$NVSMed

Novartis Pharma AG: Novartis Cosentyx becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)

Novartis' Cosentyx (secukinumab) received FDA approval for treating polymyalgia rheumatica (PMR), marking its 11th US indication. The approval follows a Phase III trial where Cosentyx doubled sustained remission rates compared to placebo. Novartis aims to address the unmet needs of PMR patients, offering an alternative to long-term steroid use. The drug is already approved in the EU and under regulatory review in Japan.

$CRSPMed

Seawolf Therapeutics San Diego $100M Sanofi DNA Deal

Seawolf Therapeutics, a San Diego biotech, raised $100M and partnered with Sanofi for a deal potentially worth $1.2B. The company's TRIDENT platform aims to enable repeat dosing of gene therapies. Seawolf's lead program targets metabolic diseases, with human trials expected by 2028. Investors include Eli Lilly, Novartis Venture Fund, and CRISPR Therapeutics.